BioLineRx Ltd. Stock News

In almost every situation, investors should stay away from penny stocks. They're extremely speculative and they tend to facilitate delusions of grandeur.

BioLineRx gains approval for a blood cancer drug that aids in stem cell transplantation. Motixafortide, the flagship drug, shows promising results in mobilizing blood stem cells and in combination wit

BioLineRx is a biopharmaceutical company specializing in cancer and rare disease therapies. The company's main product, Aphexda, was FDA-approved for stem cell mobilization in multiple myeloma patient

BioLineRx Ltd. (NASDAQ:BLRX ) Q3 2023 Earnings Conference Call November 20, 2023 10:00 PM ET Company Participants John Lacey - Head of IR & Corporate Communications Phil Serlin - CEO Holly May - Presi

The future of the U.S. economy appears to be at a pivotal juncture as the Federal Reserve maintains interest rates at a 22-year high, with the possibility of further tightening on the horizon. Despite

In general, penny stock investing is all about quick gains. Investors in this high-risk world usually are in it for a quick buck.

Penny stocks represent an exciting yet risky path to profits for active investors. Defined as stocks priced under $5 per share, these cheap equities boast the potential for astronomical returns on min

BioLineRx has received approval for their stem cell mobilizing compound, motixafortide, for certain forms of blood cancer. The compound has shown impressive results in mobilizing stem cells in patient

Bioline RX Ltd (NASDAQ:BLRX) shares jumped at the market open on Monday after the US Food and Drug Administration approved the use of Aphexda (motixafortide) in combination with filgrastim for patien

One of the safest sectors on the market is biotech. After all, we can't stop people from aging — at least not yet.

When it comes to investing in top penny stocks, a word of caution. Do your due diligence before buying.

A PDUFA date of September 9, 2023 has been established for review of Motixafortide for Autologous Transplantation in Multiple Myeloma. Results from a phase 2 Columbia University investigator study, us

Now is a great time to accumulate top undervalued biotech stocks. For one, the sector is recession-proof.

If you're like many retail traders in the stock market today, penny stocks are a popular prospect. This article looks at some of the most active penny stocks today with late-breaking momentum.

BioLineRx Ltd. (NASDAQ:BLRX ) Q1 2023 Earnings Conference Call May 24, 2023 10:00 AM ET Company Participants John Lacey - Investor Relations Philip Serlin - Chief Executive Officer Mali Zeevi - Chief